Size matters: Big hospitals with largest market shares charge highest prices
A new study of 10 cities, including Indianapolis, gives a picture of how big hospitals have been battling with big health insurers over prices—and winning.
A new study of 10 cities, including Indianapolis, gives a picture of how big hospitals have been battling with big health insurers over prices—and winning.
Paris-based Sanofi sued Eli Lilly and Co. on Thursday for patent infringement. That suit triggers an automatic 30-month delay on Lilly’s plans to launch a similar version of Sanofi’s once-a-day insulin Lantus.
A pending bill could usher in unprecedented cooperation between Indianapolis Public Schools and the city’s charter schools, resulting in significant financial benefits for both.
ITT Educational Services took it on the chin in the fourth quarter as big payments stemming from a 2009 student-loan arrangement forced an $11.6 million loss. Adding to the woes is another probe by the federal government.
Ronald Reed, the owner of Benchmark Mobility Corp., allegedly billed the Medicaid and Medicare programs for used wheelchairs, scooters and lift chairs as if they were brand new, obtaining nearly $443,000 in fraudulent sales.
Since WellPoint says it’s not losing money on the exchanges—at this point—that’s encouraging news for those who would like the Obamacare exchanges to remain a viable option.
St. Vincent Health has been sending roughly $50 million to $70 million every year to its parent company, St. Louis-based Ascension Health, to support other hospitals in Ascension’s 93-hospital network.
In spite of offers to strike a short-term extension, UnitedHealthcare and Indiana University Health are still hung up in contract negotiations on one key point: Minnesota-based UnitedHealthcare wants to create a multi-tiered network of providers and services that would offer the lowest co-pays and deductibles for favored hospital systems—which IU Health is not.
A newspaper says Eli Lilly and Co. is a leading contender to acquire a Massachusetts-based biotech company with a troubled leukemia drug.
In my financial situation, I could save from 2 percent to 30 percent buying health insurance on the Obamacare exchanges. I suspect a lot of small companies and their workers will see similar results.
Riley Hospital for Children at Indiana University Health has signed up 200 area pediatricians to be part of its new physician network. The move is the first step in an effort to build a statewide network of doctors that would use the Riley brand.
Hill-Rom Holdings Inc. will eliminate about 350 jobs over the next two years as a cost-saving move after the maker of hospital equipment saw its profit grow slower than expected.
Jim Terwilliger had led IU Health’s two flagship hospitals since July 2012, when longtime executive Sam Odle retired. The CEO of Riley Hospital for Children will replace him temporarily.
A Texas-based education organization with approval to open two Indianapolis charter schools teaches creationism and Christian-based character virtues, according to an article by Slate.com. It has prompted an expedited review of the group’s curriculum by Indianapolis and state education officials.
Interest in the Obamacare exchanges varies widely across the 14 states in which WellPoint Inc. is selling insurance plans. Indiana is near the bottom of the pile.
Congress’ recent willingness to play hardball with providers is driving providers to cautiously embrace concepts—like pay-for-performance and keeping patients out of the hospitals—they have long resisted.
There are clear signs that hospitals nationally, and even here in Indianapolis, are actually starting to make good on their promises to keep patients healthier and out of the hospital.
Many employers with fewer than 50 workers kept their health plans for 2014, but a growing number say they’ll drop group coverage at the end of this year.
IPS received 0.96 points, on a 4-point scale, based on its students’ performance in the 2012-13 school year—just shy of the full point needed to earn a D grade. Still, IPS’s score was greatly improved from the previous year.
Eli Lilly and Co.’s success at moving an experimental migraine medicine forward by using outside companies and capital is good news for this reason: The fundamental business of Big Pharma drug development is in bad shape.